NASDAQ · LNAI
Healthcare · Biotechnology
$0.16
Up+$0.00 (+0.00%)
Updated Nov 4, 2026, 11:48 PM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LNAI
1M range · 18 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
LNAI closed at $0.16 after 18 trading sessions, down 85.42% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $0.229 | $0.23 | $0.141 | $0.1648 | 1.28M |
| Oct 28, 2026 | $0.2211 | $0.25 | $0.2023 | $0.2361 | 622.78K |
| Oct 27, 2026 | $0.2576 | $0.2699 | $0.2403 | $0.2525 | 521.33K |
| Oct 26, 2026 | $0.2629 | $0.3016 | $0.2327 | $0.275 | 620.81K |
| Oct 23, 2026 | $0.26 | $0.3156 | $0.2265 | $0.2946 | 9.58M |
| Oct 22, 2026 | $0.53 | $0.53 | $0.4601 | $0.47 | 174.31K |
| Oct 21, 2026 | $0.4995 | $0.5445 | $0.4995 | $0.518 | 90.44K |
| Oct 20, 2026 | $0.49 | $0.5798 | $0.472 | $0.515 | 218.63K |
| Oct 19, 2026 | $0.6952 | $0.6952 | $0.4615 | $0.472 | 205.22K |
| Oct 16, 2026 | $0.8122 | $0.8122 | $0.6602 | $0.6804 | 79.86K |
| Oct 15, 2026 | $0.8654 | $0.9172 | $0.8178 | $0.8255 | 37.88K |
| Oct 14, 2026 | $0.9991 | $1.0054 | $0.8922 | $0.8922 | 69.62K |
| Oct 13, 2026 | $1.09 | $1.09 | $1.0101 | $1.03 | 50.36K |
| Oct 12, 2026 | $1.29 | $1.29 | $1.05 | $1.11 | 97.19K |
| Oct 9, 2026 | $1.17 | $1.68 | $0.8757 | $1.23 | 858.87K |
| Oct 8, 2026 | $1.14 | $1.15 | $1.10 | $1.12 | 14.85K |
| Oct 7, 2026 | $1.19 | $1.19 | $1.08 | $1.09 | 19.98K |
| Oct 6, 2026 | $1.13 | $1.20 | $1.13 | $1.13 | 23.64K |
The latest Smart Investors Daily articles mentioning LNAI.
Company
Market Activity
Research & News
LNAI research
Company profile and research snapshot.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Mar 5, 2026
On February 27, 2026, Lunai Bioworks Inc. (the "Company") implemented a temporary furlough of its employees in the United States and Canada as part of actions intended to preserve the Company's liquidity while it
Benzinga · Feb 17, 2026
Lunai Bioworks Inc. - Common Stock (NASDAQ:LNAI) reported quarterly losses of $(0.08) per share. This is a 82.22 percent increase over losses of $(0.45) per share from the same period last year.
Benzinga · Feb 9, 2026
Benzinga · Feb 9, 2026
AI-driven analysis of Phase 2 survival and progression data aims to identify high-benefit patient subgroups and optimize future registrational trial strategySACRAMENTO, Calif., Feb. 9, 2026 /PRNewswire/ -- Lunai Bioworks
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LNAI.
